Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Natural Killer Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04096690
What this trial is testing

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

Who this might be right for
Nasal Type Extranodal NK/T-Cell Lymphoma
Ruijin Hospital 22
Testing effectiveness (Phase 2)Study completedNCT00823524
What this trial is testing

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+6 more
Asan Medical Center 47
Early research (Phase 1)WithdrawnNCT04230330
What this trial is testing

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma
National Cancer Centre, Singapore
Not applicableStudy completedNCT02716571
What this trial is testing

Recruiting Blood Donor With Allogeneic Natural Killer Cell

Who this might be right for
Healthy Volunteers
Seoul National University Hospital 90
Testing effectiveness (Phase 2)Study completedNCT02276248
What this trial is testing

Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma

Who this might be right for
Stage I/II Extranodal NK/T-cell Lymphoma
Chinese Academy of Medical Sciences 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT02487693
What this trial is testing

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

Who this might be right for
Ovarian Carcinoma
The First People's Hospital of Changzhou 50
Testing effectiveness (Phase 2)Ended earlyNCT05011058
What this trial is testing

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

Who this might be right for
Epstein-Barr Virus Associated LymphomaEBV-Positive DLBCL, NOSEBV-Related Non-Hodgkin Lymphoma+4 more
Viracta Therapeutics, Inc. 102
Large-scale testing (Phase 3)UnknownNCT03623087
What this trial is testing

SIMPLE Chemotherapy for NK Lymphoma/Leukaemia

Who this might be right for
Non-Hodgkin's Lymphoma, RelapsedNon-Hodgkin T-cell LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
The University of Hong Kong 68
Not applicableEnded earlyNCT03249727
What this trial is testing

Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy

Who this might be right for
Immunity, InnateColorectal Cancer
ATGen Canada Inc 396
Early research (Phase 1)WithdrawnNCT02439788
What this trial is testing

3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA

Who this might be right for
Neuroblastoma
Baylor College of Medicine
Not applicableLooking for participantsNCT06015256
What this trial is testing

Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects

Who this might be right for
Asthma Acute
Institut National de la Santé Et de la Recherche Médicale, France 448
Not applicableStudy completedNCT01057459
What this trial is testing

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

Who this might be right for
Lymphoma
Alliance for Clinical Trials in Oncology 78
Not applicableStudy completedNCT01232062
What this trial is testing

Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Peking University Cancer Hospital & Institute 46
Early research (Phase 1)Study completedNCT04754100
What this trial is testing

AgenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
MiNK Therapeutics 13
Not applicableUnknownNCT04423536
What this trial is testing

Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma

Who this might be right for
Natural Killer T-cell Lymphoma
Sun Yat-sen University 800
Early research (Phase 1)Temporarily pausedNCT05629546
What this trial is testing

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Who this might be right for
Advanced MelanomaMetastatic Melanoma
Washington University School of Medicine 33
Testing effectiveness (Phase 2)Study completedNCT00418535
What this trial is testing

Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma

Who this might be right for
Lymphoma, T-Cell
Samsung Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT03329248
What this trial is testing

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Who this might be right for
Pancreatic Cancer
ImmunityBio, Inc. 6
Early research (Phase 1)Study completedNCT00161590
What this trial is testing

Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

Who this might be right for
T-Cell LymphomaLymphoma, Non-Hodgkin's
Weill Medical College of Cornell University
Early research (Phase 1)Ended earlyNCT02781467
What this trial is testing

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Leukemia, Myeloid, Acute
Celularity Incorporated 10
Next Page